Substituted tetrahydroimidazopyridine compounds corresponding to formula I: ##STR00001## in which R.sup.1, R.sup.2 and R.sup.3 have defined meanings, processes for preparing such compounds, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain, epilepsy, migraine, anxiety or urinary incontinence.
Claims The invention claimed is: 1. A substituted tetrahydroimidazopyridine compound corresponding to formula I: ##STR00058## wherein R.sup.1 and R.sup.2 each independently denote H, C.sub.1-10 alkyl, C.sub.1-4 alkyl aryl, C.sub.1-4 alkyl heteroaryl, C.sub.1-4 alkyl C.sub.3-8 cycloalkyl, C.sub.1-4 alkyl heterocyclyl or C.sub.3-8 cycloalkyl, with the proviso that R.sup.1 and R.sup.2 do not both denote H, wherein said alkyl and cycloalkyl groups may each be saturated or mono- or polyunsaturated; and said alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl groups may each be unsubstituted or mono- or polysubstituted; or R.sup.1 and R.sup.2 together with the nitrogen to which they are bound form a four- to eight-membered heterocyclic ring, optionally bridged by a C.sub.1 or C.sub.2 alkyl chain, which may contain a further heteroatom and may be substituted or unsubstituted; and R.sup.3 denotes unsubstituted or mono- or poly-substituted phenyl; wherein if one of R.sup.1 or R.sup.2 denotes H, alkyl or phenyl alkyl, the other one of R.sup.1 and R.sup.2 does not denote a group corresponding to formula X1: ##STR00059## wherein the phenyl group in formula X1 may be unsubstituted or substituted, and Y denotes a C.sub.2-5 alkyl chain or --(CH.sub.2).sub.o--Z--(CH.sub.2).sub.p--, wherein Z denotes cyclopentyl, cyclohexyl or cycloheptyl, and o and p are each 0, 1, 2 or 3, and the sum of o and p is less than or equal to 3, or a salt thereof with a physiologically acceptable acid. 2. A compound as claimed in claim 1, wherein said compound is in the form of an isolated stereoisomer. 3. A compound as claimed in claim 1, wherein said compound is in the form of a mixture of stereoisomers in any mixing ratio. 4. A compound as claimed in claim 3, wherein said mixture is a racemic mixture. 5. A compound as claimed in claim 1, wherein: "alkyl substituted", "heterocyclyl substituted" and "cycloalkyl substituted" denote the replacement of a hydrogen with F, Cl, Br, l, --CN , NH.sub.2, NH--C .sub.1-6 alkyl, NH--C .sub.1-.sub.6 alkyl-OH, C.sub.1-6 alkyl, N(C.sub.1-6 alkyl).sub.2, alkyl-OH).sub.2, NO.sub.2, SH, S--C.sub.1-6 alkyl, S-benzyl, O--C.sub.1-6 alkyl, OH, O--C.sub.1-6 alkyl-OH, .dbd.O, O-benzyl, C(.dbd.O)C.sub.1-6 alkyl, C(.dbd.O)OC.sub.1-6 alkyl, phenyl or benzyl; "aryl substituted", "phenyl substituted" and "heteroaryl substituted" denote the single or multiple substitution of one or more hydrogen atoms in the ring system with F, Cl, Br, l, CN, NH.sub.2, NH--C.sub.1-6 alkyl, NH--C.sub.1-6 alkyl-OH, N(C.sub.1-6 alkyl).sub.2, N(C.sub.1-6 alkyl-OH) .sub.2, NO.sub.2, SH, S--C.sub.1-6 alkyl, OH, O--C.sub.1-6 alkyl, O-C.sub.1-6 alkyl-OH, C(.dbd.O) aryl; C(.dbd.O)C.sub.1-6 alkyl, C(.dbd.O)NHC.sub.1-6 alkyl; C(.dbd.O)-N-morpholine; C(.dbd.O)-piperidine; (C.dbd.O)-pyrrolidine; (C.dbd.O)-piperazine; NHSO.sub.2C.sub.1-6 alkyl, NHCOC.sub.1-6 alkyl, CO.sub.2H, CH.sub.2SO.sub.2 phenyl, CO.sub.2--C.sub.1-6 alkyl, OCF.sub.3, CF.sub.3, ##STR00060## C.sub.1-6 alkyl, pyrrolidinyl, piperidinyl, morpholinyl, benzyloxy, phenoxy, phenyl, pyridyl, alkylaryl, thienyl or furyl; and wherein said C.sub.1-6 alkyl, pyrrolidinyl, piperidinyl, morpholinyl, benzyloxy, phenoxy, phenyl, pyridyl, alkylaryl, thienyl and furyl groups may themselves be substituted with F, Cl, methoxy, ethoxy, CF.sub.3, CN, CH.sub.3, OH, OCF.sub.3, SCF.sub.3 or NO.sub.2. 6. A compound as claimed in claim 1, wherein R.sup.1 and R.sup.2 each independently denote C.sub.1-10 alkyl, C.sub.1-4 alkyl aryl, C.sub.1-4 alkyl heteroaryl, C.sub.1-4 alkyl C.sub.3-8 cycloalkyl or C.sub.3-8 cycloalkyl, wherein said alkyl, aryl, heteroaryl and cycloalkyl groups may each be unsubstituted or mono- or polysubstituted. 7. A compound as claimed in claim 6, wherein R.sup.1 and R.sup.2 each independently denote H, benzyl, phenethyl, methylpyridyl, cyclopropyl, n-pentyl, n-butyl, n-hexyl, sec-butyl, propylethyl or methylcyclohexyl, and each may be unsubstituted or mono- or polysubstituted with methoxy, F, CH.sub.3, CF.sub.3 or ##STR00061## 8. A compound as claimed in claim 1, wherein R.sup.1 and R.sup.2 together with the nitrogen to which they are bound form a four- to eight-membered ring, optionally bridged by a C.sub.1 or C.sub.2 alkyl chain, which may contain a further heteroatom selected from the group consisting of O, N and S, and which may be substituted or unsubstituted. 9. A compound as claimed in claim 8, wherein R.sup.1 and R.sup.2 together with the nitrogen atom to which they are bound form a five- to seven-membered ring which may contain a further nitrogen atom and which may be unsubstituted or mono- or polysubstituted with C(O)OC.sub.2H.sub.5; C(O)C.sub.1-6 alkyl; methyl, n-butyl or acetyl; phenyl or benzyl, which each may be unsubstituted or substituted with phenyl F, Cl, Br, l, CN, CH.sub.3, C.sub.2H.sub.5, NH.sub.2, NO.sub.2, SH, CF.sub.3, OH, OCH.sub.3, OCF.sub.3, SCF.sub.3, SCH.sub.3, OC.sub.2H.sub.5 or N(CH.sub.3).sub.2. 10. A compound as claimed in claim 1, wherein R.sup.3 denotes a phenyl group, which may be unsubstituted or mono- or polysubstituted with F, Cl, Br, l, CN, CH.sub.3, C.sub.2H.sub.5, NH.sub.2, NO.sub.2, SH, CF.sub.3, OH, OCH.sub.3, OCF.sub.3, SCF.sub.3, SCH.sub.3, phenoxy, OC.sub.2H.sub.5 or N(CH.sub.3).sub.2. 11. A compound as claimed in claim 1, selected from the group consisting of: 1 (4-Benzylpiperidin-1-yl)(6-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]p- yridin-2-yl) methanone; 2 N-Benzyl-N-phenethyl-6-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-- carboxamide; 3 (6-Phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(1,3,3-trimethyl-6- -azabicyclo [3.2.1]octan-6-yl)methanone; 4 (6-(3-Fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(1,3,3-t- rimethyl-6-azabicyclo[3.2.1]octan-6-yl)methanone; 5 N-Benzyl-6-(4-methoxy-3,5-dimethylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a ]pyridine-2-carboxamide; 6 (4-(2-Fluorophenyl)piperazin-1-yl)(6-(4-methoxy-3,5-dimethylphenyl)-5,6,7- ,8-tetrahydroimidazo [1,2-a]pyridin-2-yl)methanone; 7 (6-(5-Fluoro-2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-y- l)(4-(3-(trifluoromethyl) phenyl)piperazin-1-yl)methanone; 8 (4-Benzylpiperidin-1-yl)(6-(5-fluoro-2-methoxyphenyl)-5,6,7,8-tetrahydroi- midazo [1,2-a]pyridin-2-yl)methanone; 9 (6-(5-Fluoro-2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-y 1)(1,3,3-trimethyl-6-azabicyclo[3.2.1]octan-6-yl)methanone; 10 (6-(4-Methoxy-3,5-dimethylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin- -2-y 1)(4-(2-methoxyphenyl)piperazin-1-yl)methanone; 11 (4-Benzylpiperidin-1-yl)(6-(4-ethylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-- a ]pyridin-2-yl)methanone; 12 (6-(2,5-Dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(1,- 3,3-trimethyl -6-azabicyclo[3.2.1]octan-6-yl)methanone; 13 (6-(4-Fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl- )(4-(2-fluorophenyl) piperazin-1-yl)methanone; 14 6-(4-Fluoro-3-methylphenyl)-N-(1-phenylethyl)-5,6,7,8-tetrahydroimidazo[1- ,2-a ]pyridine-2-carboxamide; 15 6-(4-Methoxy-3,5-dimethylphenyl)-N-pentyl-5,6,7,8-tetrahydroimidazo[1,2-a ]pyridine-2-carboxamide; 16 N-Hexyl-6-(4-methoxy-3,5-dimethylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a ]pyridine-2-carboxamide; 17 6-(4-Methoxy-3,5-dimethylphenyl)-N-(3-(trifluoromethyl)benzyl)-5,6,7,8-te- trahydroimidazo [1,2-a]pyridine-2-carboxamide; 18 N-sec-Butyl-6-(4-phenoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-- 2-carboxamide; 19 N-Butyl-6-(4-phenoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-ca- rboxamide; 20 Ethyl 1-(6-(4-phenoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carbony- l) piperidine-4-carboxylate; 21 (4-Methylpiperidin-1-yl)(6-(4-phenoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,- 2-a ]pyridin-2-yl)methanone; 22 Ethyl 1-(6-(4-phenoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carbony- l) piperidine-3-carboxylate; 23 1-(4-(6-(4-Phenoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carb- onyl) piperazin-1-ypethanone; 24 6-(4-Phenoxyphenyl)-N-(pyridin-3-ylmethyl)-5,6,7,8-tetrahydroimidazo[1,2-- a ]pyridine-2-carboxamide; 25 (6-(4-Phenoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(pyrrol- idin-1-yl) methanone; 26 N-Cyclopropyl-6-(4-phenoxyphenyl)-5,6.sub.17,8-tetrahydroimidazo[1,2-a]py- ridine-2-carboxamide; 27 N-(3,4-Dimethoxyphenethyl)-6-(4-phenoxyphenyl)-5,6,7,8-tetrahydroimidazo[- 1,2-a ]pyridine-2-carboxamide; 28 N-Pentyl-6-(4-phenoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-c- arboxamide; 29 Pyrrolidin-1-yl(6-m-tolyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)me- thanone; 30 (6-(3,5-Bis(trifluoromethyl)phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrid- in-2-yl) (pyrrolidin-1-yl)methanone; 31 Pyrrolidin-1-yl(6-(3-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydroimidazo[1- ,2-a ]pyridin-2-yl)methanone; 32 (4-(2-Fluorophenyl)piperazin-1-yl)(6-(3-(trifluoromethyl)phenyl)-5,6,7,8-- tetrahydroimidazo [1,2-a]pyridin-2-yl)methanone; 33 (6-(2,4-Dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(py- rrolidin-1-yl)methanone; 34 Pyrrolidin-1-yl(6-o-tolyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)me- thanone; 35 (6-o-Tolyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(3-(trifluorom- ethyl)-phenyl) piperazin-1-yl)methanone; 36 (6-(2,5-Difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(pyr- rolidin-1-yl methanone; 37 (6-(4-Ethylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(pyrrolid- in-1-yl) methanone; 38 (6-(4-Fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(1,3,3-t- rimethyl-6-azabicyclo[3.2.1]octan-6-yl)methanone; 39 6-(4-Methoxyphenyl)-N-(3-(trifluoromethyl)benzyl)-5,6,7,8-tetrahydroimida- zo[1,2-a ]pyridine-2-carboxamide; 40 6-(4-Ethylphenyl)-N-phenethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-- carboxamide; 41 (4-Benzylpiperidin-1-yl)(6-(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2- -a ]pyridin-2-yl)methanone; 42 N-(Benzo[d][1,3]dioxo1-5-ylmethyl)-6-(3,5-bis(trifluoromethyl)phenyl)-5,6- ,7,8-tetrahydroimidazo [1,2-a]pyridine-2-carboxamide; 43 N-Benzyl-6-(3,5-bis(trifluoromethyl)phenyl)-5,6,7,8-tetrahydroimidazo[1,2- -a ]pyridine-2-carboxamide; 44 (6-(4-Methoxy-3,5-dimethylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin- -2-yl) (4-(4-methoxyphenyl)piperazin-1-yl)methanone; 45 (4-(2-Ethoxyphenyl)piperazin-1-yl)(6-m-tolyl-5,6,7,8-tetrahydroimidazo[1,- 2-a ]pyridin-2-yl)methanone; 46 (6-(2,4-Dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-- (3-(trifluoromethyl) phenyl)piperazin-1-yl)methanone; 47 (6-(4-Fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(3-(t- rifluoromethyl) phenyl)piperazin-1-yl)methanone; 48 (6-(3-Fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(3-(t- rifluoromethyl) phenyl)piperazin-1-yl)methanone; 49 N-(4-Fluorobenzyl)-6-(4-methoxy-3,5-dimethylphenyl)-5,6,7,8-tetrahydroirn- idazo-[1,2-a]pyridine-2-carboxamide; 50 (4-Benzylpiperidin-1-yl)(6-(3-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,- 2-a ]pyridin-2-yl)methanone; 51 6-(3-Fluorophenyl)-N-(4-phenylbutan-2-yl)-5,6,7,8-tetrahydroimidazo[1,2-a ]pyridine-2-carboxamide; 52 6-(4-Ethylphenyl)-N-(4-phenylbutan-2-yl)-5,6,7,8-tetrahydroimidazo[1,2-a ]pyridine-2-carboxamide; 53 (6-Phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(3-(trifluorome- thyl) phenyl)piperazin-1-yl)methanone; 54 (6-(4-Methoxy-3,5-dimethylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin- -2-yl) (4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)methanone; 55 (4-Benzylpiperidin-1-yl)(6-(4-methoxy-3,5-dimethylphenyl)-5,6,7,8-tetrahy- dro-imidazo [1,2-a]pyridin-2-yl)methanone; 56 (6-(4-Methoxy-3,5-dimethylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin- -2-y) (1,3,3-trimethyl-6-azabicyclo[3.2.1]octan-6-yl)methanone; 57 4-Benzylpiperidin-1-yl)(6-(4-fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimi- dazo [1,2-a]pyridin-2-yl)methanone; 58 (6-(4-Fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl- )(4-(3-(trifluoromethyl) phenyl)piperazin-1-yl)methanone; 59 (4-Benzhydrylpiperazin-1-yl)(6-(4-methoxy-3,5-dimethylphenyl)-5,6,7,8-tet- rahydroimidazo [1,2-a]pyridin-2-yl)methanone; 60 6-(3-Methoxyphenyl)-N-(4-phenylbutan-2-yl)-5,6,7,8-tetrahydroimidazo[1,2-- a ]pyridine-2-carboxamide; 61 (4-Benzylpiperidin-1-yl)(6-(3-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2- -a ]pyridin-2-yl)methanone; 62 (6-(4-Fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl- )(4-(4-(trifluoromethyl) phenyppiperazin-1-yl)methanone; 63 (6-(4-Fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl- )(4-(4-fluorophenyl) piperazin-1-yl)methanone; 64 (6-(4-Fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl- )(4-(4-methylphenyl) piperazin-1-Arnethanone; 65 (6-(4-Fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl- )(4-(3-methylphenyl) piperazin-1-yl)methanone; 66 (4-Butylpiperazin-1-yl)(6-(4-fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimi- dazo [1,2-a]pyridin-2-ylynethanone; 67 (4-Benzhydrylpiperidin-1-yl)(6-(4-fluoro-3-methylphenyl)-5,6,7,8-tetrahyd- ro-imidazo [1,2-a]pyridin-2-yl)methanone; 68 N-(Cyclohexylmethyl)-6-(4-fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimidaz- o[1,2-a ]pyridine-2-carboxamide; 69 (6-(4-Methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(3-(- trifluoromethyl) phenyl)piperazin-1-yl)methanone; 70 (4-Benzylpiperidin-1-yl)(6-m-tolyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridi- n-2-yl) methanone; 71 (6-(3-Methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(3-(- trifluoromethyl) phenyppiperazin-1-yl)methanone; 72 6-(4-Fluoro-3-methylphenyl)-N-(4-phenylbutan-2-yl)-5,6,7,8-tetrahydroimid- azo-[1,2-a]pyridine-2-carboxamide; 73 4-Benzylpiperidin-1-yl)(6-p-tolyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin- -2-yl) methanone; 74 (6-p-Tolyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(3-(trifluorom- ethyl)-phenyl) piperazin-1-Amethanone; 75 (6-m-Tolyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(3-(trifluorom- ethyl)-phenyl) piperazin-1-yl)methanone; 76 (4-Benzylpiperidin-1-yl)(6-(4-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,- 2-a ]pyridin-2-yl)methanone; 77 (6-(3,5-Dimethylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(- 3-(trifluoromethypphenyl) piperazin-1-yl)methanone; 78 N-(1-(3,5-Dimethylphenypethyl)-6-(4-fluoro-3-methylphenyl)-5,6,7,8-tetrah- ydroimidazo [1,2-a]pyridine-2-carboxamide; 79 6-(3,4-Difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(3- -(trifluoromethyl) phenyl)piperazin-1-yl)methanone; 80 (4-Benzylpiperazin-1-yl)(6-(4-fluoro-3-methylphenyl)-5,6,7,8-tetrahydro-i- midazo [1,2-a]pyridin-2-yl)methanone; 81 (6-(4-Phenoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(3-(- trifluoromethyl) phenyppiperazin-1-yDrnethanone; 82 6-(4-(Benzyloxy)phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)(4-(- 3-(trifluoromethyl) phenyppiperazin-1-yl)methanone; 83 (6-(4-Fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl- )(4-(3-fluorophenyl) piperazin-1-yl)methanone; 84 (6-(4-Fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl- )(1,3,3-trimethyl-6-azabicyclo[3.2.1]octan-6-yl)methanone; 85 (6-(4-Fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl- )(4-(3-(trifluoromethyl) phenyl)piperidin-1-yl)methanone; 86 6-(4-Fluoro-3-methylphenyl)-N-(4-(3-(trifluoromethyl)phenyl)butan-2-yO-5,- 6,7,8-tetrahydroimidazo [1,2-a]pyridine-2-carboxamide; 87 6-(4-Fluoro-3-methylphenyl)-N-methyl-N-(4-(3-(trifluoromethyl)phenyl)buta- n-2-yl) -5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxamide; and 88 N-(2-Cyclohexylethyl)-6-(4-fluoro-3-methylphenyl)-5,6,7,8-tetrahydroimida- zo[1,2-a ]pyridine-2-carboxamide. 12. A pharmaceutical composition comprising a compound as claimed in claim 1, and at least one pharmaceutically acceptable carrier or auxiliary substance. 13. A method of treating pain in a subject, said method comprising administering to said subject a pharmacologically effective amount of a compound as claimed in claim 1. 14. A method as claimed in claim 13, wherein said pain is selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain and inflammatory pain. 15. A method of treating a condition selected from the group consisting of pain, epilepsy, migraine, anxiety and urinary incontinence in a subject, said method comprising administering to said subject a pharmacologically effective amount of a compound as claimed in claim 1. 16. A process for preparing a compound as claimed in claim 1, according to the following reaction scheme: ##STR00062## said process comprising: a) reacting an iodine-, bromine- or chlorine-substituted 2-aminopyridine with 3-bromo -2-oxopropionic acid in an organic solvent at a temperature between 0.degree. C. and 80.degree. C. for 2 to 48 hours to yield an iodine-, bromine- or chlorine-substituted imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester; b) reacting the iodine-, bromine- or chlorine-substituted imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester from a) with a phenylboric acid or phenylboric acid ester in a solvent using a catalyst, a base and optionally an additive; c) cleaving the carboxylic acid ester using an organic or aqueous inorganic acid or an aqueous inorganic base in an organic solvent to yield a substituted imidazopyridine carboxylic acid; d) hydrogenating the substituted imidazopyridine carboxylic acid from c) with a hydrogenation catalyst in a solvent under normal pressure or elevated pressure to yield a tetrahydroimidazopyridine carboxylic acid; and e) reacting the tetrahydroimidazopyridine carboxylic acid from d) with a primary or secondary amine using a base, and optionally a coupling reagent, in a solvent. 17. A process as claimed in claim 16, wherein: said solvents are independently selected from the group consisting of methanol, ethanol, 1-propanol, ethylene glycol, water, THF, 1,2-dimethoxyethane, acetone, chloroform, dioxane, acetonitrile, DMF, benzene, toluene, xylene, dichloromethane, diethyl ether, acetic acid, propionic acid, DCM, cyclohexane or methanolic KOH; said carboxylic acid ester is cleaved with trifluoroacetic acid or aqueous hydrochloric acid or an aqueous based selected from the group consisting of lithium hydroxide, potassium hydroxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate or potassium carbonate; said hydrogenation catalyst is selected from the group consisting of Pd on activated carbon, Raney nickel, platinum or PtO.sub.2; said base is selected from the group consisting of sodium methanolate, TEA, DIEA or N-methylmorpholine; and said coupling reagent is selected from the group consisting of EDCI, HOBt, DCC, CDI, HBTU, DMAP or pentafluorophenyl diphenyl phosphinate. 